Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change, 9/14 – 9/17/2014, Sheraton Seattle Hotel, Seattle WA
Reporter: Aviva Lev-Ari, PhD, RN
PLENARY KEYNOTE SESSION
IT TAKES A VILLAGE: DEFINING PRECISION MEDICINE
Northwest BioTrust: Consented Specimens, Medical Data and Patient Registry
John T. Slattery, Ph.D., Vice Dean, Research and Graduate Education, School of Medicine; Professor, Pharmacology and Medicine,
University of Washington School of Medicine
Integrating the Principles of Preventative and Personalized Care to Advance Wellness
Nathan D. Price, Ph.D., Associate Director, Institute for Systems Biology
My Avatars for Kids
James M. Olson, M.D., Ph.D., Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor, Pediatric
Hematology and Oncology, University of Washington; Attending Physician, Seattle Children’s Hospital; Founder, Presage Biosciences
The National Biomarkers Development Alliance (NBDA): Advancing Biomarkers Development for Precision Medicine Beginning with Biospecimens
Carolyn Compton, M.D., Ph.D., CMO, National Biomarkers Development Alliance; Professor, School of Life Sciences, Arizona State University
THE ROADMAP TO PRECISE MEDICINE
Integrating Laboratory and Clinical Informatics for Next-Generation Sequencing Assays
Noah Hoffman, M.D., Ph.D., Assistant Professor, Laboratory Medicine, University of Washington
Successful Implementation of Precision Medicine in Clinical Cancer Care: The UW Experience
Colin C. Pritchard, M.D., Ph.D., Assistant Professor and Associate Director, Genetics and Solid Tumors Laboratory, Laboratory Medicine,
University of Washington
PERSONALIZED GENOMICS: PLATFORMS AND PATHWAYS
Glycan “Node” Analysis for Detecting and Monitoring Cancer
Chad R. Borges, Ph.D., Assistant Professor, Chemistry and Biochemistry, The Biodesign Institute – Center for Personalized Diagnostics,
Arizona State University
Novel Technologies Enabling Exploratory Biomarker Analysis in the Clinic
Rajiv Raja, Ph.D., Group Leader, Clinical Assays and Technologies Group, Oncology Biomarker Development, Genentech, Inc.
Integrative Genomic Analysis of Gastric Cancer
Kai Wang, Ph.D., Principal Scientist, Oncology Research Unit, Pfizer, Inc.
Development and Validation of a Clinical Trial Patient Stratification Assay that Interrogates 27 Mutation Sites in MAPK Pathway Genes
Ken C.N. Chang, Ph.D., Clinical Assay Development and Outsourcing Lead, Clinical Biomarkers and Diagnostics, Merck & Co., Inc.
An Inducible, Isogenic Cancer Cell Line System for Targeting the State of Mismatch Repair Deficiency
Julie Bailis, Ph.D., Senior Scientist, Oncology Research, Amgen, Inc.
PATIENT-DERIVED MODELS (PDX) AS TRANSLATIONAL PLATFORMS FOR ONCOLOGY THERAPIES
Featured Presentation
Development of New Therapeutic Agents Targeting Key Cancer Stem Cell Pathways
Timothy Hoey, Ph.D., Senior Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.
Next-Generation Patient-Derived Prostate Cancer Xenograft Models
Yuzhuo Wang, Ph.D., Associate Professor, Urologic Sciences, University of British Columbia
Understanding Cancer Stem Cells in Human Melanoma Using a Patient-Derived Tumor Xenograft Model
Mayumi Fujita, M.D., Ph.D., Associate Professor, University of Colorado Denver School of Medicine
Fluorescently Labeled Chimeric Anti-CEA Antibody Improves Detection and Resection of Gastrointestinal Cancers in Patient-Derived
Orthotopic Xenograft (PDOX) Nude Mouse Models
Michael Bouvet, M.D., Professor, Surgery; Director, Endocrine Surgery; Co-Director, GI Cancer Unit, Moores Cancer Center,
University of California, San Diego
Molecular Characterization of Patient-Derived Human Pancreatic Tumor Xenograft Models for Preclinical and Translational Development of Cancer Therapeutics
Pia Challita-Eid, Director, Molecular Biology, Agensys, Inc. (tentative)
For sponsorship and exhibit sales information, please contact:
Carolyn Benton
Business Development Manager
781-972-5412 | cbenton@healthtech.com
SOURCE
http://www.healthtech.com/precision-medicine-cancer
From: Precision Medicine for Cancer Diagnosis <kerris@healthtech.com>
Date: Wed, 16 Apr 2014 09:59:00 -0400
To: <avivalev-ari@alum.berkeley.edu>
Subject: Preliminary Agenda Now Available
Leave a Reply